PharmiWeb.com - Global Pharma News & Resources
13-Jun-2019

Hemoglobinopathy Market is Projected to Jump USD 12 Billion by 2026

Global Hemoglobinopathy Market Size is expected to reach USD 12 Billion by 2026 and will grow at a CAGR around 10.0 % during the forecast period.

The global Hemoglobinopathy Market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2019 to 2026. The report offers of historic and future market scenario in terms of market value, share and critical developments taking place in the industry. Market size, forecast, trends of each country and region are studied in the report for the focus period of 2019 to 2026.

Request a Sample Copy of this Research Report at https://www.acumenresearchandconsulting.com/request-sample/1382

Qualitative assessment tools such as PEST analysis, cost structure analysis and regulatory compliance for pharmaceutical products are offered in the report. The report also comprises Pipeline Analysis which helps understand the comprehensive forecast scenario of the market in terms of value and dynamics. The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in the global Hemoglobinopathy Market.

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market.

The market is studied for regions such as North America (U.S., and Canada), Europe (U.K., Germany, France, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East amp; Africa (GCC, South Africa, and Rest of Middle East amp; Africa).

Key Takeaways:

  • What is the market size in 2018 and the growth rate of the global Hemoglobinopathy Market market?
  • What is the market drivers, restrains, opportunities governing the global Hemoglobinopathy Market Market?
  • Which is the largest and the fastest growing segments in the global Hemoglobinopathy Market market?
  • Who are the key players operating in the market and their market position?
  • What is the pipeline scenario, drug pricing analysis and technological development in the market?

To Purchase this Premium Report at https://www.acumenresearchandconsulting.com/buy-now/0/1382

Market Players:

With the presence of regional and local players, the world Hemoglobinopathy market is fragmented. The market has been acquired by major companies by key manufacturers. Alnylam Pharmaceuticals; Gamida Cell; Global Blood Therapeutics Inc.; bluebird media Inc.; Emmaus Life Sciences Inc.; Sanofi: Prolong Pharmaciens; and Celgene Corporation are the main business competitors.

Key competitors focus on cooperation and licensing agreements for the exchange of technical knowledge linked to therapeutic haemoglobinopathy. For example, in January 2014, the global cooperation agreement for therapeutic development of hemoglobinopathy was announced by Bioverativ and Sangamo Therapeutics, Inc.

The Major Market Segments of GlobalHemoglobinopathy Marketare as below:

Market Segmentation

Market, By Type

  • Thalassemia
    • Beta Thalassemia
    • Alpha Thalassemia
  • Sickle Cell Disease
  • Other Hb Variants Diseases

Market, By Therapy

  • Thalassemia
    • Beta Thalassemia
    • Alpha Thalassemia
  • Sickle Cell Disease
  • Other Hb Variants Diseases

Market, By Diagnosis

  • Thalassemia
    • Beta Thalassemia
    • Alpha Thalassemia
  • Sickle Cell Disease
  • Other Hb variants diseases

Market, By Geography

  • North America.
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

The market research study on Hemoglobinopathy Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026offers detailed insights on global Hemoglobinopathy market segments with market dynamics and their impact. The report also covers basic technology development policies.

The report provides an analysis of the latest industry trends from 2015 to 2026 in all sub-segment segments and forecasts revenue and volume growth on the global, the regional and country levels.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Hemoglobinopathy
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Hemoglobinopathy Market By Type
1.2.2.1. Global Hemoglobinopathy Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Hemoglobinopathy Market Revenue Share By Type in 2017
1.2.2.3. Thalassemia
1.2.2.4. Beta Thalassemia
1.2.2.5. Alpha Thalassemia
1.2.2.6. Sickle Cell Disease
1.2.2.7. Other Hb Variants Diseases
1.2.3. Hemoglobinopathy Market By Therapy
1.2.3.1. Global Hemoglobinopathy Market Revenue and Growth Rate Comparison By Therapy (2015-2026)
1.2.3.2. Thalassemia
1.2.3.3. Beta Thalassemia
1.2.3.4. Alpha Thalassemia
1.2.3.5. Sickle Cell Disease
1.2.3.6. Other Hb Variants Diseases
1.2.4. Hemoglobinopathy Market By Diagnosis
1.2.4.1. Global Hemoglobinopathy Market Revenue and Growth Rate Comparison By Diagnosis (2015-2026)
1.2.4.2. Thalassemia
1.2.4.3. Beta Thalassemia
1.2.4.4. Alpha Thalassemia
1.2.4.5. Sickle Cell Disease
1.2.4.6. Other Hb variants diseases
1.2.5. Hemoglobinopathy Market by Geography
1.2.5.1. Global Hemoglobinopathy Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Hemoglobinopathy Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Hemoglobinopathy Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Type of Global Hemoglobinopathy Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Hemoglobinopathy Major Manufacturers in 2017

CHAPTER 4. HEMOGLOBINOPATHY MARKET BY BY TYPE

4.1. Global Hemoglobinopathy Revenue By Type
4.2. Thalassemia
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Beta Thalassemia
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Alpha Thalassemia
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Sickle Cell Disease
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Other Hb Variants Diseases
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. HEMOGLOBINOPATHY MARKET BY THERAPY

5.1. Global Hemoglobinopathy Revenue By Therapy
5.2. Thalassemia
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Beta Thalassemia
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Alpha Thalassemia
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Sickle Cell Disease
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Other Hb Variants Diseases
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. HEMOGLOBINOPATHY MARKET BY DIAGNOSIS

6.1. Global Hemoglobinopathy Revenue By Diagnosis
6.2. Thalassemia
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Beta Thalassemia
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Alpha Thalassemia
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Sickle Cell Disease
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. Other Hb variants diseases
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA HEMOGLOBINOPATHY MARKET BY COUNTRY

7.1. North America Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Hemoglobinopathy Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. U.S.
7.3.1. U.S. Hemoglobinopathy Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE HEMOGLOBINOPATHY MARKET BY COUNTRY

8.1. Europe Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Hemoglobinopathy Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC HEMOGLOBINOPATHY MARKET BY COUNTRY

9.1. Asia-Pacific Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Hemoglobinopathy Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA HEMOGLOBINOPATHY MARKET BY COUNTRY

10.1. Latin America Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Hemoglobinopathy Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST HEMOGLOBINOPATHY MARKET BY COUNTRY

11.1. Middle East Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Hemoglobinopathy Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA HEMOGLOBINOPATHY MARKET BY COUNTRY

12.1. Africa Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Hemoglobinopathy Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Alnylam Pharmaceuticals
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Gamida Cell
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Global Blood Therapeutics Inc.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. bluebird media Inc.
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Emmaus Life Sciences Inc
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Sanofi
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Prolong Pharmaciens
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Celgene Corporation
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Others
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

To Purchase this Premium Report at https://www.acumenresearchandconsulting.com/buy-now/0/1382

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 13-Jun-2019